A Multi-Center Trial of the ProLung Test™
Status: | Active, not recruiting |
---|---|
Conditions: | Lung Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 12/21/2018 |
Start Date: | October 2012 |
End Date: | March 2019 |
A Multi-Center Trial of the ProLung Test™ (Transthoracic Bioconductance Measurement) as an Adjunct to CT Chest Scans for the Risk Stratification of Patients With Pulmonary Lesions Suspicious for Lung Cancer
The primary Study hypothesis is that the ProLung Test will demonstrate safety and efficacy in
the risk stratification of patients with pulmonary lesions identified by CT that are
suspicious for lung cancer. A statistically significant result will indicate that patients
with a high ProLung Test result have a greater risk of developing lung cancer than patients
with a low test result.
There are three Specific Aims of this study:
1. Optimize and confirm the stability of the ProLung Test risk-stratification algorithm in
patients with a diagnosis.
2. Externally validate the efficacy of the ProLung Test risk-stratification algorithm by
comparing the test result to the conclusive patient diagnosis.
3. Assess the safety and tolerability of the ProLung Test procedures.
Study Design This Study consists of two distinct phases, Stabilization and Validation. The
Study will collect data from multiple sites (3 to 12), and each site may enroll patients and
collect data for the Stabilization and Validation Phases with a minimum of three sites for
the Validation Phase.
the risk stratification of patients with pulmonary lesions identified by CT that are
suspicious for lung cancer. A statistically significant result will indicate that patients
with a high ProLung Test result have a greater risk of developing lung cancer than patients
with a low test result.
There are three Specific Aims of this study:
1. Optimize and confirm the stability of the ProLung Test risk-stratification algorithm in
patients with a diagnosis.
2. Externally validate the efficacy of the ProLung Test risk-stratification algorithm by
comparing the test result to the conclusive patient diagnosis.
3. Assess the safety and tolerability of the ProLung Test procedures.
Study Design This Study consists of two distinct phases, Stabilization and Validation. The
Study will collect data from multiple sites (3 to 12), and each site may enroll patients and
collect data for the Stabilization and Validation Phases with a minimum of three sites for
the Validation Phase.
Inclusion Criteria:
Subjects who meet all of the following criteria may be enrolled in this Study:
1. Subject is male or female, age 18 or older.
2. Subject has undergone CT scan of the lung(s) that indicates one or more nodules or
lesions suspicious for lung cancer.
3. Subject's pulmonary nodule or lesion is greater than 4mm. Size is determined by the
largest nodule or lesion dimension identified from CT imaging.
4. Subject meets one or more of the following conditions:
- indicated for a tissue biopsy
- indicated for surgical resection of the lung
5. Subject must be able to receive a ProLung Test
- within 60 days of abnormal CT (Inclusion Criterion 2 & 3)
- within 60 days prior to the tissue biopsy or surgical resection (Inclusion
Criterion 4).
6. Subject is capable of understanding and agreeing to fulfill the requirements of this
Protocol.
7. Subject has signed the IRB/IEC approved Informed Consent Form ("ICF").
Exclusion Criteria
The following criteria will disqualify a subject from enrollment into this Study:
1. Subject has an implanted electronic device in the chest.
2. Subject receiving therapy for suspected chest infection such as fungal infection or
tuberculosis.
3. Subject with diagnosed malignancy other than lung cancer, non-melanoma skin cancer or
any cancer in which the Principal Investigator does not suspect metastatic disease to
the lung, who has 2 or more suspicious pulmonary nodules.
4. Subject has received an invasive medical or surgical procedure within the thoracic
cavity within 30 days prior to the ProLung Test or within the previous 14 days for a
bronchoscopic procedure.
5. Subject presents with an anomalous physical or anatomical condition that precludes
ProLung Test measurement.
6. Subject will have undergone unusually strenuous exercise within 24 hours.
7. Subject who has significant systemic diseases such as uncontrolled diabetes, advanced
heart failure, or a recent myocardial infarction, or other medical condition such as
severe morbid obesity that in the judgment of the Principal Investigator would make
him/her unsuitable for the Study.
We found this trial at
15
sites
Minneapolis, Minnesota 55455
Principal Investigator: Ahmad Raza, MD
Phone: 612-672-5151
Click here to add this to my saved trials

Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
Click here to add this to my saved trials

171 Ashley Avenue
Charleston, South Carolina 29425
Charleston, South Carolina 29425
843-792-1414

Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Click here to add this to my saved trials

Detroit, Michigan 48202
Principal Investigator: Michael Simoff, MD
Phone: 313-916-3558
Click here to add this to my saved trials

Houston, Texas 77030
Principal Investigator: David Ost, MD
Phone: 713-745-2645
Click here to add this to my saved trials

757 Westwood Plaza
Los Angeles, California 90024
Los Angeles, California 90024
(310) 825-9111

Phone: 310-206-0396
UCLA Medical Center Founded in 1955, UCLA Medical Center became Ronald Reagan UCLA Medical Center...
Click here to add this to my saved trials

2160 South 1st Avenue
Maywood, Illinois 60153
Maywood, Illinois 60153
(888) 584-7888

Principal Investigator: Amit Goyal, MD
Phone: 708-216-2027
Loyola University Medical Center Loyola University Health System is committed to excellence in patient care...
Click here to add this to my saved trials

Murray, Utah 84107
Principal Investigator: Denitza Blagev, MD
Phone: 801-507-4608
Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

34800 Bob Wilson Drive
San Diego, California 92103
San Diego, California 92103
Principal Investigator: Samir Makani, MD
Phone: 858-449-7218
Click here to add this to my saved trials

300 Pasteur Dr
Stanford, California 94305
Stanford, California 94305
(650) 723-4000

Principal Investigator: Arthur W Sung, MD
Phone: 650-497-2929
Stanford Univ Med Ctr The Medical Center is uniquely advantaged by its location on the...
Click here to add this to my saved trials

Towson, Maryland 21204
Principal Investigator: Rex Yung, MD
Phone: 443-849-3285
Click here to add this to my saved trials

Waco, Texas 76712
Principal Investigator: Boris Murillo, MD
Phone: 245-751-4128
Click here to add this to my saved trials

Winston-Salem, North Carolina 27157
Principal Investigator: Clifford Howard, MD
Phone: 336-713-4747
Click here to add this to my saved trials
